In the BioHarmony Drug Report Database

"Preview" Icon

Erdafitinib

Balversa (erdafitinib) is a small molecule pharmaceutical. Erdafitinib was first approved as Balversa on 2019-04-12. It is used to treat transitional cell carcinoma in the USA. It is known to target fibroblast growth factor receptor 2, fibroblast growth factor receptor 4, vascular endothelial growth factor receptor 2, fibroblast growth factor receptor 1, and fibroblast growth factor receptor 3. Balversa’s patents are valid until 2038-02-02 (FDA).

 

Trade Name

 

Balversa
 

Common Name

 

erdafitinib
 

ChEMBL ID

 

CHEMBL3545376
 

Indication

 

transitional cell carcinoma
 

Drug Class

 

Tyrosine kinase inhibitors

Image (chem structure or protein)

Erdafitinib structure rendering